<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3049">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04320472</url>
  </required_header>
  <id_info>
    <org_study_id>Neuro-COVID-19</org_study_id>
    <nct_id>NCT04320472</nct_id>
  </id_info>
  <brief_title>Acute Encephalopathy in Critically Ill Patients With COVID-19</brief_title>
  <acronym>NeuroCOVID19</acronym>
  <official_title>Outcomes in Patients With Acute Encephalopathy and SARS-Cov-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ictal Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ictal Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infection with SARS-CoV-2 or severe acute respiratory syndrome coronarvirus type 2 was&#xD;
      highlighted in December 2019 in the city of Wuhan in China, responsible for an pandemic&#xD;
      evolution since March 11, 2020. The infection affects all ages of life, although affecting&#xD;
      children in a very small proportion of cases. The typical presentation of the disease&#xD;
      combines fever (98%), cough (76%), myalgia and asthenia (18%) as well as leukopenia (25%) and&#xD;
      lymphopenia (63%). Upper airway involvement rare.&#xD;
&#xD;
      The main clinical presentation requiring hospitalization of infected patients is that of&#xD;
      atypical pneumonia which may require critical care management (27%), and progress to an acute&#xD;
      respiratory distress syndrome (67%) involving life-threatening conditions in almost 25% of&#xD;
      patients diagnosed with SARS-CoV-2 infection. Other organ damage have been reported, mainly&#xD;
      concerning kidney damage (29%) which may require renal replacement therapy in approximately&#xD;
      17% of patients.&#xD;
&#xD;
      Neurological damage has been very rarely studied, yet reported in 36% of cases in a study&#xD;
      including patients of varying severity.&#xD;
&#xD;
      Finally, the mortality associated with this emerging virus is high in patients for whom&#xD;
      critical care management is necessary, reported in 62% of patients.&#xD;
&#xD;
      We therefore propose a prospective observational study which aim at reporting the prevalence&#xD;
      of acute encephalopathy at initial management in Critical/Intensive care or Neurocritical&#xD;
      care , to report its morbidity and mortality and to identify prognostic factors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients with SARS-CoV-2 infection and acute encephalopathy at presentation will be&#xD;
      prospectively included in the NEURO-COVD-19 study. This study will collect demographic data,&#xD;
      clinical examen at prehospital/emergency room and ICU admission (including neurological&#xD;
      signs), and all ancillary exams performed to identify a cause of neurological impairment.&#xD;
      Outcome will be evaluated using the Glasgow Outcome Scale score at ICU and hospital&#xD;
      discharge, and day-90 after ICU admission.&#xD;
&#xD;
      Acute encephalopathy will be defined as recently stated :&#xD;
&#xD;
      &quot;1. The term acute encephalopathy refers to a rapidly developing (over less than 4 weeks, but&#xD;
      usually within hours to a few days) pathobiological process in the brain. This is a preferred&#xD;
      term 2. Acute encephalopathy can lead to a clinical presentation of subsyndromal delirium,&#xD;
      delirium, or in case of a severely decreased level of consciousness, coma; all representing a&#xD;
      change from baseline cognitive status 3. The term delirium refers to a clinical state&#xD;
      characterized by a combination of features defined by diagnostic systems such as the DSM-5.&#xD;
      Delirium according to the DSM-5 is defined if criterium A-E are fulfilled: A. Disturbance in&#xD;
      attention (i.e., reduced ability to direct, focus, sustain, and shift attention) and&#xD;
      awareness (reduced orientation to the environment). B. The disturbance develops over a short&#xD;
      period of time (usually hours to a few days) represents a change from baseline attention and&#xD;
      awareness, and tends to fluctuate in severity during the course of the day. C. An additional&#xD;
      disturbance in cognition (e.g., memory deficit, disorientation, language, visuospatial&#xD;
      ability, or perception). D. The disturbances in criteria A and C are not explained by another&#xD;
      pre-existing, established, or evolving neurocognitive disorder, and do not occur in the&#xD;
      context of a severely reduced level of arousal, such as coma. E. There is evidence from the&#xD;
      history, physical examination, or laboratory findings that the disturbance is a direct&#xD;
      physiologic consequence of another medical condition, substance intoxication or withdrawal&#xD;
      (i.e. because of a drug of abuse medication), or exposure to a toxin, or is because of&#xD;
      multiple etiologies. &quot; (Slooter, A.J.C., Otte, W.M., Devlin, J.W. et al. Updated nomenclature&#xD;
      of delirium and acute encephalopathy: statement of ten Societies. Intensive Care Med (2020).&#xD;
      https://doi.org/10.1007/s00134-019-05907-4)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 23, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>prevalence</measure>
    <time_frame>at Critical/Intensive care or Neurocritical care admission</time_frame>
    <description>ratio of patients with acute encephalopathy among the total of patients with SARS-Cov-2 infection at Critical/Intensive care or Neurocritical care admission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Favorable outcome</measure>
    <time_frame>3 months</time_frame>
    <description>A favorable outcome is defined by a Glasgow Outcome Scale (GOS) of 5. The Glasgow Outcome Scale (GOS) will be determined patients charts review, phone call, and/or general practitioner interview conducted by an independent assessor. The GOS score : [1: Death, 2: Persistent vegetative state, 3: Severe disability, 4: Moderate disability, 5 : Low disability]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Favorable outcome</measure>
    <time_frame>3 months</time_frame>
    <description>A favorable outcome is defined by a Glasgow Outcome Scale Extended (GOSe) &gt;= 5. The Glasgow Outcome Scale Extended (GOSe) will be determined patients charts review, phone call, and/or general practitioner interview conducted by an independent assessor. The GOSe score : [1: Death, 2: Persistent vegetative state, 3: Severe disability Lower, 4: Severe disability Upper, 5: Moderate disability Lower, 6: Moderate disability Upper, 7 : Good recovery lower, 8 : Good recovery Upper]</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">250</enrollment>
  <condition>COVID-19</condition>
  <condition>Encephalopathy</condition>
  <condition>Critically Ill</condition>
  <arm_group>
    <arm_group_label>Follow up</arm_group_label>
    <description>Follow up of all included patients up to 3 months after enrollement</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Follow up</intervention_name>
    <description>Follow up up to day 90 (Glasgow outcome scale, Glasgow outcome scale extended, functionnal impairments : Barthel index, Disability Rating Scale)</description>
    <arm_group_label>Follow up</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Acute encephalopathy and ICU admission&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Critical/Intensive care or Neurocritical care admission&#xD;
&#xD;
          -  Admission for/with acute encephalopathy defined as a rapidly developing (over less&#xD;
             than 4 weeks, but usually within hours to a few days) pathobiological process in the&#xD;
             brain; including delirium or subsyndromal (DSM V definition) or coma (Glasgow coma&#xD;
             scale score &lt; 9)&#xD;
&#xD;
          -  SARS-COV-2 infection (respiratory or other PCR specimen)&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Opposition to study participation from the patient itself or patient surrogate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Stephane LEGRIEL, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ictal Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jackson Memorial Health System; University of Miami, Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellstar Atlanta Medical Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de SÃ£o Paulo</name>
      <address>
        <city>SÃ£o Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FundaciÃ³n Valle del Lili, University Hospital</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cairo University Hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Argenteuil</name>
      <address>
        <city>Argenteuil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Beauvais</name>
      <address>
        <city>Beauvais</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Ambroise ParÃ©</name>
      <address>
        <city>Boulogne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Bourg en Bresse</name>
      <address>
        <city>Bourg-en-Bresse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier RÃ©gional Universitaire de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Brives</name>
      <address>
        <city>Brive-la-Gaillarde</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Beaujon</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Henri Mondor</name>
      <address>
        <city>CrÃ©teil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Dieppe</name>
      <address>
        <city>Dieppe</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Etampes</name>
      <address>
        <city>Etampes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand HÃ´pital de l'Est Francilien - Site de Marne-la-VallÃ©e</name>
      <address>
        <city>Jossigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Roche-sur-Yon</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de La Rochelle</name>
      <address>
        <city>La Rochelle</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire HÃ´pital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital privÃ© Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Sud Ile-de-France</name>
      <address>
        <city>Melun</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier RÃ©gional d'OrlÃ©ans</name>
      <address>
        <city>OrlÃ©ans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe hospitalier Paris Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Fondation Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital PrivÃ© Claude Galien</name>
      <address>
        <city>Quincy-sous-SÃ©nart</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Roanne</name>
      <address>
        <city>Roanne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Toulon</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave-Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional De Alta Especialidad Del BajÃ­o</name>
      <address>
        <city>Guanajuato</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Universitari</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Egypt</country>
    <country>France</country>
    <country>Mexico</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 22, 2020</study_first_submitted>
  <study_first_submitted_qc>March 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2020</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

